Neovii
Research, development, manufacturing and sale of life-changing drugs for orphan diseases
Neovii is a global biopharmaceutical company specializing in the research and development, manufacturing, marketing and sale of life-changing biologic drugs that address the needs of patients suffering from orphan diseases. The company's products, intended for the treatment of patients with complex medical needs in transplantation and immunological and hematological disorders, are sold in more than 60 countries. With headquarters in Switzerland and a manufacturing facility in Germany, the company has local offices in several countries around the world.
We provide innovative therapeutic solutions for patients with severe diseases whose medical needs have so far gone unmet. Our products are derived from the extensive experience, expertise and commitment of our employees and partners around the world.
The company's leading product is Grafalon®, indicated for the prevention of complications in patients undergoing organ and bone marrow transplants. With more than 200,000 patients already treated and international recognition among transplant medical teams, Grafalon has changed the way solid organ and stem cell transplant teams manage patient care around the world.
In addition, Neovii is developing an innovative enzyme replacement therapy for mitochondrial neurogastrointestinal encephalopathy (MNGIE).